We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
On 15 May 2012, Advocate General Mazak gave an opinion on AstraZeneca’s appeal against a General Court judgment which largely upheld the European Commission’s decision to fine AstraZeneca for abusive patent misuse
On 31 January 2012, the Commission stated that it had opened a formal investigation into Samsung’s use of standard essential patents and whether that amounts to a breach of Article 102
On 14 November 2011, the Office of Fair Trading announced that it has opened an investigation under Article 101 and Article 102 TFEU into certain patent litigation settlement agreements relating to paroxetine, a medicine used in the treatment of disorders such as depression and anxiety disorder
In a new judgment that further explores the application of competition law to intellectual property rights, the EU General Court has upheld a 2005 Commission decision finding that AstraZeneca abused a market-dominant position by blocking or delaying the entry of generic versions of its ulcer drug Losec
